Adimmune Corporation (4142.TW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Chi-Hsien Chan
|
CEO & Chairman | 24.04M | -- | -- |
|
Mr. Chin-Chuan Chang
|
COO and VP of R&D | 5.34M | -- | -- |
|
Mr. Chin-I Chiu
|
Vice President of Quality Assurance Department | 5.13M | -- | -- |
|
Jade Hsu
|
Chief Financial Officer | -- | -- | -- |
|
Ms. Li-Ya Tang
|
Director of Administration Center | -- | -- | -- |
|
Chih-Hsiang Leng
|
Head of R&D Division | -- | -- | -- |
|
Yuan Hou Yan
|
Deputy Chief Operating Officer | -- | -- | -- |
Adimmune Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 14, 2021 at 12:00 AM UTC
Ex-Dividend Date
